Patents by Inventor Casey Kopczynski

Casey Kopczynski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ophthalmic compositions
    Patent number: 11707460
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: July 25, 2023
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • Isoquinoline-steroid conjugates and uses thereof
    Patent number: 11691950
    Abstract: Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 4, 2023
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
  • DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTS
    Publication number: 20230094779
    Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of a the device.
    Type: Application
    Filed: August 12, 2022
    Publication date: March 30, 2023
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
  • Ophthalmic compositions
    Patent number: 11590123
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: February 28, 2023
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • OPHTHALMIC COMPOSITIONS
    Publication number: 20220409607
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Application
    Filed: August 24, 2022
    Publication date: December 29, 2022
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • OPHTHALMIC COMPOSITIONS
    Publication number: 20220331308
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Application
    Filed: July 6, 2022
    Publication date: October 20, 2022
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • OPHTHALMIC COMPOSITIONS
    Publication number: 20220304995
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Application
    Filed: June 15, 2022
    Publication date: September 29, 2022
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • Ophthalmic compositions
    Patent number: 11389441
    Abstract: The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: July 19, 2022
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
  • COMBINATION THERAPY
    Publication number: 20220088000
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Combination therapy
    Patent number: 11197853
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: December 14, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Compositions for treating glaucoma or reducing intraocular pressure
    Patent number: 11185538
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: November 30, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • ISOQUINOLINE-STEROID CONJUGATES AND USES THEREOF
    Publication number: 20210300874
    Abstract: Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 30, 2021
    Inventors: Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
  • IMPLANTABLE DEVICE FOR DELIVERY OF THERAPEUTIC SUBSTANCES TO THE EYE
    Publication number: 20210251892
    Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.
    Type: Application
    Filed: December 21, 2020
    Publication date: August 19, 2021
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
  • COMPOSITIONS FOR TREATING GLAUCOMA OR REDUCING INTRAOCULAR PRESSURE
    Publication number: 20210244722
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Application
    Filed: April 23, 2021
    Publication date: August 12, 2021
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • COMBINATION THERAPY
    Publication number: 20210236477
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Application
    Filed: April 23, 2021
    Publication date: August 5, 2021
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Isoquinoline-steroid conjugates and uses thereof
    Patent number: 11059789
    Abstract: Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. Also provided herein are methods of treating an eye disease or disorder in a subject. Also provided herein are methods of reducing intraocular pressure in a subject. Also provided herein are methods of modulating kinase activity in a cell. Also provided herein are methods of making the compounds provided herein, and compounds useful for the preparation of the compounds provided herein.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: July 13, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
  • Combination therapy
    Patent number: 11020385
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: June 1, 2021
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Drug delivery devices for delivery of ocular therapeutic agents
    Patent number: 10869833
    Abstract: Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: December 22, 2020
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Chris Sutay
  • Combination Therapy
    Publication number: 20200276179
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Application
    Filed: February 3, 2020
    Publication date: September 3, 2020
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • COMBINATION THERAPY
    Publication number: 20200129498
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 30, 2020
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong